Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials

Robert E. Shapiro, Amaal J. Starling, Erin Doty et al.|The Journal of Headache and Pain|2019

Cited by 88